BACKGROUND: The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho. METHODS: All adult patients initiating antiretroviral therapy from January 1, 2008, to December 31, 2008, were included in the analysis and followed until December 31, 2009. Choice of regimen was determined by clinical criteria. RESULTS: Of 1124 patient records analyzed, median age was 39 years, and the majority (67.7%) were women. Five hundred eighty-seven patients were started on tenofovir, 255 on zidovudine, and 282 on stavudine. Patients on zidovudine were more than twice as likely to experience a toxicity-driven regimen substitution compared with tenofovir (adjusted hazard ratio: 2.32, 95% confidence interval: 1.23 to 4.40); for patients on stavudine, the risk of a toxicity-driven regimen switch was almost 6 times higher than tenofovir (adjusted hazard ratio: 5.43, 95% confidence interval: 3.31 to 8.91). CONCLUSIONS: Our findings support the latest World Health Organization Guidelines, in particular the adoption of tenofovir in first line, given the advantages in terms of tolerability and availability as a once-daily formulation.
BACKGROUND: The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited settings. We report on outcomes and toxicities among patients on these different regimens in a routine treatment cohort in Lesotho. METHODS: All adult patients initiating antiretroviral therapy from January 1, 2008, to December 31, 2008, were included in the analysis and followed until December 31, 2009. Choice of regimen was determined by clinical criteria. RESULTS: Of 1124 patient records analyzed, median age was 39 years, and the majority (67.7%) were women. Five hundred eighty-seven patients were started on tenofovir, 255 on zidovudine, and 282 on stavudine. Patients on zidovudine were more than twice as likely to experience a toxicity-driven regimen substitution compared with tenofovir (adjusted hazard ratio: 2.32, 95% confidence interval: 1.23 to 4.40); for patients on stavudine, the risk of a toxicity-driven regimen switch was almost 6 times higher than tenofovir (adjusted hazard ratio: 5.43, 95% confidence interval: 3.31 to 8.91). CONCLUSIONS: Our findings support the latest World Health Organization Guidelines, in particular the adoption of tenofovir in first line, given the advantages in terms of tolerability and availability as a once-daily formulation.
Authors: Rachael Bonawitz; Alana T Brennan; Lawrence Long; Timothy Heeren; Mhairi Maskew; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2018-05-04 Impact factor: 2.622
Authors: Sowmyanarayanan V Thuppal; Christine A Wanke; Farzad Noubary; Joshua T Cohen; Mkaya Mwamburi; Abraham C Ooriapdickal; Jayaprakash Muliyil; Gagandeep Kang; George M Varghese; Priscilla Rupali; Rajiv Karthik; Rajkumar Sathasivam; Peace Clarance; Susanne A Pulimood; Dincy Peter; Leni George Journal: Trans R Soc Trop Med Hyg Date: 2015-03-15 Impact factor: 2.184
Authors: Alana T Brennan; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2014-03-03 Impact factor: 2.622
Authors: Viktor von Wyl; Valentina Cambiano; Michael R Jordan; Silvia Bertagnolio; Alec Miners; Deenan Pillay; Jens Lundgren; Andrew N Phillips Journal: PLoS One Date: 2012-08-08 Impact factor: 3.240
Authors: Alana T Brennan; Mary-Ann Davies; Jacob Bor; Gilles Wandeler; Kathryn Stinson; Robin Wood; Hans Prozesky; Frank Tanser; Geoffrey Fatti; Andrew Boulle; Izukanji Sikazwe; Kara Wool-Kaloustian; Constantin Yuannoutsos; Valériane Leroy; Nathalie de Rekeneire; Matthew P Fox Journal: AIDS Date: 2017-01-02 Impact factor: 4.632
Authors: Alana T Brennan; Jacob Bor; Mary-Ann Davies; Gilles Wandeler; Hans Prozesky; Geoffrey Fatti; Robin Wood; Kathryn Stinson; Frank Tanser; Till Bärnighausen; Andrew Boulle; Izukanji Sikazwe; Arianna Zanolini; Matthew P Fox Journal: Am J Epidemiol Date: 2018-09-01 Impact factor: 5.363